Part of the weight loss market was hit hard in 2020 as the COVID-19 pandemic and ensuing recession forced the closure of health clubs and many retail weight loss centers.

After the great shock exerted by the COVID-19 pandemic on the global economy, as well as on world trade, 2021 fortunately marked the beginning of a path to recovery.

The global biologics market is expected to see a 12% growth rate and reach $420.55 billion by 2025, according to a new report by The Business Research Company.

Because the pegfilgrastim biosimilars market is highly concentrated with only a few large players, gaining an in-depth understanding of the top competitors and their key strategies is crucial. A new report by The Business Research Company provides detailed information on the pegfilgrastim biosimilars competitive landscape. Read on to learn key insights from the report.

The COVID-19 pandemic has sped up the adoption of artificial intelligence (AI) in the pharma market in domains such as healthcare.

One of the new classes of vaccines, mRNA-based vaccines facilitate cells in the body to make specific proteins for triggering an immune response, further producing antibodies against a specific disease.

As obesity rates climb and Americans age, more people are developing sleep apnea, restless leg syndrome and other sleep disorders. Plus, stress in 2020 related to the presidential election, Covid-19 pandemic and recession are all contributing to more sleepless nights.

International trade data can represent an accurate barometer of the state of the health of the global economy, even more so in the current extraordinary circumstances, that require up-to-date monitoring for companies involved in international business.

For the pharmaceutical industry and the broader scientific community, creating and producing effective COVID-19 vaccines has been a challenge and opportunity of a lifetime — a chance to help save humanity from an urgent global crisis.